Cytokinetics' (CYTK) omecamtiv Approval Highly Likely, Data Are Encouraging and Suggest Useful Benefit, Reiterate Buy - H. C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 62.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.03 | 52 Week High | $13.18 | |||
| Open | $62.03 | 52 Week Low | $6.00 | |||
| Day High | $62.03 | P/E | N/A | |||
| Day Low | $62.03 | EPS | $-1.24 | |||
| Volume | 14 | |||||
